Theranexus SA (FR:ALTHX) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Theranexus, in collaboration with the Beyond Batten Disease Foundation, has announced promising phase I/II trial results for Batten-1 in treating Batten disease CLN3, showing potential in stabilizing visual acuity. These findings, presented at the Child Neurology Society Annual Meeting, support the advancement to a phase III trial, with visual acuity as the primary endpoint. The company is exploring options to fund the next trial phase, highlighting its commitment to advancing treatment for this rare disease.
For further insights into FR:ALTHX stock, check out TipRanks’ Stock Analysis page.